Portal de Periódicos da CAPES

The Interaction of Thiol Drugs and Urine pH in the Treatment of Cystinuria

2012; Lippincott Williams & Wilkins; Volume: 189; Issue: 6 Linguagem: Inglês

10.1016/j.juro.2012.12.031

1527-3792

Daniel M. Asplin, John R. Asplin,

Porphyrin Metabolism and Disorders

No AccessJournal of UrologyAdult Urology1 Jun 2013The Interaction of Thiol Drugs and Urine pH in the Treatment of Cystinuria Daniel M. Asplin and John R. Asplin Daniel M. AsplinDaniel M. Asplin Financial interest and/or other relationship with Litholink and Oxthera. More articles by this author and John R. AsplinJohn R. Asplin Financial interest and/or other relationship with Litholink and Oxthera. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.12.031AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Pharmacological therapy for cystinuria consists of alkali salts to increase urine pH and thiol drugs to form soluble cysteine-drug complexes. The effect of alkalinizing urine on thiol drug activity has not been well studied. Materials and Methods: Urine samples were obtained from 5 healthy subjects and pH was adjusted (range 6.0 to 8.0) in each urine aliquot. Urine samples were incubated with cystine crystals at 37C for 5, 15 and 60 minutes, and 48 hours. We compared cystine solubility in urine samples spiked with thiol drugs at a final concentration of 2 mM to that in control urine samples at the various pH levels and time points. Results: In samples incubated for 48 hours, which is the standard time frame for solubility studies, cystine solubility more than doubled with thiol drugs compared to control and did not depend on pH. However, when incubation time was shortened to 5 minutes, representing the dwell time of urine in the renal pelvis, the effect of thiol drugs to solubilize cystine greatly depended on urine pH with less cystine dissolved at lower pH. Conclusions: Increasing urine pH greatly increased the efficacy of thiol drugs to solubilize cystine in a clinically relevant time frame. These findings suggest that to maximize the benefit of thiol drugs alkali therapy should be used in conjunction with thiol drugs with the goal of keeping urine pH at 7.5 or above. Clinical trials are needed to confirm these in vitro findings. References 1 : Pathophysiology and treatment of cystinuria. Nat Rev Nephrol2010; 6: 424. Google Scholar 2 : Pathophysiology and management of cystine stones. In: Urolithiasis: Medical and Surgical Management. Edited by . London: Informa2009: 105. chapt 9. Google Scholar 3 : Clinical use of cystine supersaturation measurements. J Urol2000; 164: 1481. Link, Google Scholar 4 : Assessment of cystine solubility and heterogenous nucleation. J Urol1983; 129: 1066. Abstract, Google Scholar 5 : The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol1984; 22: 273. Google Scholar 6 : Dietary restriction of sodium as a means of reducing urinary cystine. J Urol1990; 143: 1193. Link, Google Scholar 7 : Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol2005; 19: 429. Google Scholar 8 : Comparison of 2-mercaptopropionylglycine and D-penicillamine in the treatment of cystinuria. J Urol1986; 136: 146. Link, Google Scholar 9 : Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol1986; 136: 1003. Link, Google Scholar 10 : New agent in the treatment of cystinuria: N-acetyl-D-penicillamine. Br Med J1968; 1: 284. Google Scholar 11 : Mechanisms of action of D-penicillamine and n-acetyl D-penicillamine in the therapy of cystinuria. Clin Sci1968; 35: 467. Google Scholar 12 : Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol2001; 166: 688. Link, Google Scholar 13 : Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int2006; 69: 1041. Google Scholar 14 : The expectation of free and fixed particles in urinary stone disease. Invest Urol1978; 15: 442. Google Scholar 15 : The spectrum of metabolic abnormalities in patients with cystine nephrolithiasis. J Urol1989; 141: 819. Link, Google Scholar 16 : Effect of captopril on urinary cystine excretion in homozygous cystinuria. J Urol1989; 142: 1522. Link, Google Scholar 17 : Ineffectiveness of captopril in reducing cystine excretion in cystinuric children. J Inherit Metab Dis1993; 16: 1042. Google Scholar 18 : Cystinosis: practical tools for diagnosis and treatment. Pediatr Nephrol2011; 26: 205. Google Scholar 19 : The history of cystinosis: lessons for clinical management. Int J Nephrol2011; 2011. 929456. Google Scholar 20 : Effect of penicillamine on cystinuria. Br Med J1963; 1: 588. Google Scholar 21 : Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol2008; 180: 2620. Link, Google Scholar 22 : Medical therapy of cystinuria: evaluation in a mouse model. J Urol2010; 183: e509. Link, Google Scholar 23 : Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Relat Areas Mol Biol1990; 63: 69. Google Scholar 24 : Theoretical insights into the mechanism for thiol/disulfide exchange. Chemistry2004; 10: 257. Google Scholar 25 : Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol Med1999; 27: 322. Google Scholar 26 : Metabolism of cysteamine. J Pharmacol Exp Ther1957; 121: 258. Google Scholar Litholink Corp., Chicago, Illinois© 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAssimos D (2020) Re: Assessment of Health-Related Quality of Life in Patients with Cystinuria on Tiopronin TherapyJournal of Urology, VOL. 204, NO. 1, (180-180), Online publication date: 1-Jul-2020.Assimos D (2020) Re: CRISPR/Cas9 Engineering of Albino Cystinuria Type A MiceJournal of Urology, VOL. 204, NO. 3, (613-614), Online publication date: 1-Sep-2020.Assimos D (2019) Re: Metabolic Consequences of CystinuriaJournal of Urology, VOL. 202, NO. 6, (1091-1093), Online publication date: 1-Dec-2019.Assimos D (2019) Re: Urine Proteomic Profiling in Patients with Nephrolithiasis and CystinuriaJournal of Urology, VOL. 202, NO. 1, (25-25), Online publication date: 1-Jul-2019.Assimos D (2018) Re: Associating Mutations Causing Cystinuria with Disease Severity with the Aim of Providing Precision MedicineJournal of Urology, VOL. 199, NO. 4, (887-888), Online publication date: 1-Apr-2018.Assimos D (2017) Re: α-Lipoic Acid Treatment Prevents Cystine Urolithiasis in a Mouse Model of CystinuriaJournal of Urology, VOL. 198, NO. 5, (975-975), Online publication date: 1-Nov-2017.Assimos D (2016) Re: Can the Presence of Crystalluria Predict Stone Formation in Patients with Cystinuria?Journal of Urology, VOL. 197, NO. 1, (169-170), Online publication date: 1-Jan-2017.Assimos D (2015) Re: Urine Proteomic Analysis in Cystinuric Children with Renal StonesJournal of Urology, VOL. 194, NO. 5, (1427-1427), Online publication date: 1-Nov-2015.Assimos D (2015) Re: CKD and its Risk Factors among Patients with CystinuriaJournal of Urology, VOL. 194, NO. 5, (1313-1314), Online publication date: 1-Nov-2015.Assimos D (2013) Re: Further Delineation of Genotype-Phenotype Correlation in Homozygous 2p21 Deletion Syndromes: First Description of Patients without CystinuriaJournal of Urology, VOL. 191, NO. 3, (679-680), Online publication date: 1-Mar-2014.Assimos D (2013) Re: The Effect of Prophylactic Treatment with Shohl’s Solution in Children with CystinuriaJournal of Urology, VOL. 190, NO. 5, (1894-1894), Online publication date: 1-Nov-2013. Volume 189Issue 6June 2013Page: 2147-2151 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordstiopronincaptoprilurinary bladderhydrogen-ion concentrationurolithiasisMetricsAuthor Information Daniel M. Asplin Financial interest and/or other relationship with Litholink and Oxthera. More articles by this author John R. Asplin Financial interest and/or other relationship with Litholink and Oxthera. More articles by this author Expand All Advertisement PDF downloadLoading ...